CPT code 81513 represents a molecular diagnostic assay that analyzes RNA markers from a vaginal fluid specimen for three bacterial species and applies an algorithm to report a positive or negative bacterial vaginosis (BV) result. This code captures both the technical amplification and the downstream algorithmic interpretation that yields a clinically actionable BV determination. As molecular and algorithm-based diagnostics expand, CPT code 81513 is significant for payers and laboratories because it combines laboratory analytics with an interpretive software component, affecting coverage, coding clarity, and reimbursement pathways.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical use, typical sites of service, and the role of algorithmic interpretation in BV testing. The report outlines benchmarks and coding context relevant to laboratories and billing teams, highlights payer considerations, and summarizes clinical implications for diagnosing bacterial vaginosis using nucleic acid amplification with automated interpretation. Data not available in the input is noted where applicable. The content is intended for national audiences involved in laboratory operations, medical billing, and payer policy.